A new study determines which vaccine compounds are safe and effective when used as a booster

56% of mankind have already received the first dose of the COVID-19 vaccine. Today 45% of people have a complete plan with immunization. 3.2% agreed to receive a third dose Shortly after the completion of the program, further increase protection against corona virus, hospitalization and reduce the risk of death.

A study conducted in the United Kingdom and published in a special journalThe Lancet Shows that six different Covit-19 vaccines are safe and effective when used as booster doses. That is, the third dose works better because of a different vaccine.

On A comparative study of seven different vaccine brands, British researchers found that most people showed a strong immune system when given a third dose. Among them, The Messenger RNA vaccine injections provided by Moderna and Pfizer-BioNTech revealed the greatest responses.

This is a second phase test that analyzes the safety and efficacy of seven vaccines given after two initial doses of the Oxford-Astrogeneca or Pfizer-Bioentech vaccine. The vaccines included in the study were manufactured by Oxford-AstraZeneca, Pfizer-BioEntech, NovaVox, Johnson & Johnson, Modernna, Volneva and Kurevac.

Officials from the Centers for Disease Control and Prevention, who are concerned about preliminary reports about Omigran, said Monday that all adults should receive a booster dose. The first confirmed case of this variation was filed Wednesday in San Francisco, against a man who returned to South Africa on November 22nd. The person, who had mild symptoms, was said to be improving and had a full vaccination schedule, but no booster dose was available.

The study involved 2,878 adults over the age of 30, and it concluded None of the seven vaccines had safety concerns when used as a booster dose. Fatigue, headaches and pain at the injection site are the most common side effects that often occur in young people. A total of 912 participants experienced adverse effects from the booster vaccine, 24 of which were severe during the study.

Professor Sal Fast, experimental director and director of the NIHR Center for Medical Research at the University of Southampton Hospital in the UK, said: “Our data on side effects show that all seven of our vaccines are safe to use as a third dose.

He further added:After two doses of AstraZeneca, seven levels of antibodies against the spike protein were significantly increased. However, Only six people did so after two doses of Pfizer-BioNTech (AstraZeneca, Pfizer-BioNTech, Moderna, Novavax, Janssen and CureVac). There were big differences in response with different reinforcements ”.

After analyzing the results, Dr. Fast further commented: “It is very encouraging to see the benefits of any of these vaccines as a booster dose, using a variety of techniques. It gives confidence and flexibility in the development of reinforcement projects around the world, and other factors such as supply chain and logistics are at risk. ”

According to the authors of the study, participants were ‘in good health’ and were recruited from 18 different locations in the UK. Nearly half received two doses of the Oxford-AstraZeneca vaccine, while the rest of the group was vaccinated with the Pfizer-Bioentech vaccine. Half of the participants in the study were over 70 years of age. Some individuals were included in a control group and given the meningococcal vaccine as a placebo.

Four weeks after the boosters were given, the researchers measured the participants’ antibody levels. Corona targets the spike protein of the virus. Spike protein is an important part of the structure of the corona virus that allows it to enter human cells. D-cell reactions that play a key role in the fight against viral infections and can affect the severity of Covit-19 have also been observed. These results were measured by concern for alpha, beta and delta variants, as well as original distortions that first appeared in China.

According to the study, all seven vaccines boosted immunity when given as a booster dose within 10 to 12 weeks. After two doses of the Oxford-AstraZeneca vaccine. According to the study, all vaccines except Valneva boosted immunity in participants.

Among the participants who received two doses of the Oxford-Astrogeneca vaccine, antibody levels against the spike protein were 1.8 times higher (after Valneva) and 32.3 times higher (after Moderna) after 28 days, depending on the booster shot used. . Among those who received the first two doses of Pfizer-BioNTech, the increase in antibody levels after boosters was 1.3 times (after Valneva) to 11.5 times (after Modernna).

“These data are welcomed by policymakers,” said Marine Voice, a statistician at Oxford University who was not involved in the study. “The most important news we take home is that there are plenty of great third-dose booster options,” he said.

The study authors clarified that they did not examine the effectiveness of different combinations of boosters in preventing transmission, hospitalization, and death from Covit-19. They added that the relationship between stimulus and antibody levels after four weeks of long-term immunity was unknown.

Other limitations of the task were the age limit of the participants, the majority of the study participants were white and the short time between doses, which, according to the authors of the report, reduced immune responses. . The research team is therefore examining the effects of boosters seven to eight months after the initial doses expected in 2022.

Dr. Fast further commented that other tasks are being carried out “that will generate data three months and one year after receiving the reinforcements, which will allow us to know their impact on long-term safety and immune memory.”

The third dose is already used in 58 countries. Israel and Chile have already used the third dose for 45% of their general population. Iceland (40%), Uruguay (38%), the United Arab Emirates (30%), the United Kingdom (27%) and Hungary (26%) also used the third level. For Argentina, the use of the third dose, in addition or reinforcement, began in November and has so far reached 4.7% of the general population.

In the UK, most people are given the Pfizer-Bioentech vaccine or the Moderna vaccine as a stimulant, although some are given the Oxford-Astrogene vaccine if they cannot find an alternative. Yesterday he The British government has announced that it has signed new agreements to purchase an additional 114 million doses of Pfizer / Bioentech and Modern vaccines between 2022 and 2023., In order to guarantee its reinforcement program if a new Omicron variant of the corona virus appears. You plan to use them as a fourth dose.

In the United States, the FDA, the regulatory authority, has already approved the use of the Moderna and Pfizer-BioNtech vaccines in the country’s booster program, and only the Pfizer-Bioentech vaccine is used in Israel.

In Argentina, four out of every five people (81.3% of the population) received at least one dose of the vaccine against COVID-19. Two-thirds (66.6%) have at least two doses and more than two million people (4.7%) already have three doses.. As reported Infobe On Wednesday, for the past three weeks, the rate of third doses has already been higher than the first dose.

For the summer, In Argentina, it is expected to improve with a third booster dose, which includes the possibility of combining vaccines from AstraZeneca, Pfizer / Bioendech, Moderna and Sputnik V at the Kamaleya Institute in Russia, but they will be used. Depending on the availability of the moment reported to Infobe Dr. Juan Manuel Castelli, Under Secretary of State for Health Strategies, Ministry of Health.

One limitation of the booster dose study is that this was done long before the omigron variant of anxiety appeared.. When a person is exposed to the omega-3 variant of the corona virus, a booster dose with 90% effectiveness against parental stress may provide less protection, but it is not known how bad it is. Scientists must first figure out how to further cultivate that variation in the laboratory.

Dr. Fast and his colleagues have already sent blood samples from test volunteers to British government laboratories, where researchers will see how well their immune cells work against their antibodies and omicron. “I think we’ll start seeing those results in a few weeks,” Dr. Fast said. If the boosters do not work properly against that variant, vaccine developers will have to make new injections. Messenger RNA vaccines can be quickly modified to target Omicron mutations.

Continue reading: